Navigation Links
Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
Date:9/21/2007

DANBURY, Conn., Sept. 21 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that the Company has expanded its two ongoing pivotal Phase III clinical trials of VIAject(TM) into Europe. Clinical sites have been initiated in Germany and patient treatment has begun.

"We are expanding VIAject(TM)'s pivotal Phase III trials into Europe to support our planned European registration of VIAject(TM)," stated Dr. Solomon S. Steiner, Chairman and CEO of Biodel. "Given the worldwide prevalence of diabetes, we are determined to establish VIAject(TM) as a global solution. Evaluating VIAject(TM)'s therapeutic profile in European patients with Type 1 and Type 2 diabetes gives us the opportunity to demonstrate VIAject(TM)'s clinical outcomes across a more diverse patient population."

VIAject(TM) is currently undergoing two pivotal Phase III clinical studies. The two studies, one enrolling 400 Type 1 diabetic patients and the other enrolling 400 Type 2 diabetic patients, are comparing the effects of VIAject(TM) to Humulin(R) R, the leading recombinant human insulin. Both studies are open label and involve a treatment regimen that is six months in duration. Clinical endpoints of both trials include non-inferiority in terms of HbA1c levels and safety.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA- approved peptide drugs. The Company's lead product candidate, VIAject(TM), is a rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in Phase I clinical trials and tw
'/>"/>

SOURCE Biodel Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Biodel Inc. to Present VIAject Clinical Progress at the 2007 American Diabetes Association Meeting
2. PromegaExpress Expands Easy Access to Products with New Cabinet
3. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
4. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
5. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
6. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...- ChemoCentryx,Inc.,announcedtodaythatPhaseII/III...veRandomizedOralTherapyEvaluationinCrohn,sdiseaseT...rate-to-severeCrohn,sdiseasedemonstratedclinicalef...hestudydemonstratedevidenceofclinicalefficacyinthe...easeintheCrohn,sDiseaseActivityIndex(CDAI)inpatien...
(Date:11/24/2009)...ll/--Endologix,Inc.(Nasdaq: ELGX ),developerofmini...dtodaythatithasfiledamotiontostay,ordiscontinueall...gainstitinOctober2009byCook,Inc.Themotionwasfiledi...a. ,, Endologixhasrequestedthatthestayremainine...USPTO)conductsproceedingstore-examinethetwopatents...
(Date:11/24/2009)...AnadysPharmaceuticals,Inc.(Nasdaq: ANDS )announced...ealthcareConferenceonTuesday,December1,2009at9:00a...ewYorkPalaceHotel.SteveWorland,Ph.D.,PresidentandC...ofAnadysanditsclinicaldevelopmentprograms,ANA598an...taneouslywebcastandcanbeaccessedontheInvestorRelat...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2Metropolitan Chicago Breast Cancer Task Force Announced Members of Chicago Breast Cancer Quality Consortium 60440 1Metropolitan Chicago Breast Cancer Task Force Announced Members of Chicago Breast Cancer Quality Consortium 60440 2Metropolitan Chicago Breast Cancer Task Force Announced Members of Chicago Breast Cancer Quality Consortium 60440 3Metropolitan Chicago Breast Cancer Task Force Announced Members of Chicago Breast Cancer Quality Consortium 60440 4Metropolitan Chicago Breast Cancer Task Force Announced Members of Chicago Breast Cancer Quality Consortium 60440 5AARP Commends Legislature For Saving Critical Health Care Program 60438 1Detroit Clinic Owner Pleads Guilty in Medicare Fraud Scheme 60436 1Detroit Clinic Owner Pleads Guilty in Medicare Fraud Scheme 60436 2Detroit Clinic Owner Pleads Guilty in Medicare Fraud Scheme 60436 3Detroit Clinic Owner Pleads Guilty in Medicare Fraud Scheme 60436 4
...stern Time - , , SOUTH SAN FRANCISCO, Calif., Ma... ), a biopharmaceutical company focused on oncolog...quarter ended March 31, 2009, and provided a corpo...f our pivotal Phase 3 SPEAR trial of picoplatin fo...cer, along with the independent Data Monitoring Co...
... and Cognition-Related Fatty Acid are Important to...May 5 The strong preference kids with autism have...onal deficiencies because their diets lack suffici... Children,s Hospital Medical Center at this year,s.... , , After presenting their findings on May 4, t...
Other Medicine Technology:Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update 9Lack of Food Variety Puts Kids With Autism at Risk for Poor Nutrition 2Lack of Food Variety Puts Kids With Autism at Risk for Poor Nutrition 3
(Date:11/25/2009)...ILVERSPRING,Md.,Nov.25/PRNewswire-USNewswire/--Ana...rforDrugEvaluationandResearch,titled"ADifficultBal...ntheNov.26,2009issueofTheNewEnglandJournalofMedici...nh/20090824/FDALOGO ) ,, Inthearticle,Woodcockd...ainmedicationforthosewhoneeditandmanagingtherisksp...
(Date:11/25/2009)...hers have found evidence of a statistically signif...ng patients whose estrogen receptor (ER)-positive ...pha; at serine-118 (ER-alpha S118-P), according to...5 in the Journal of the National Cancer Institute...resistant to tamoxifen. Preclinical studies have s...
(Date:11/25/2009)... Evaluation and treatment clinics ... Woodstock (Vocus) November 25, 2009 -- Centegra...accines and H1N1 vaccine shots at four Centegra Pr... shipment of vaccine has arrived. The clinics are ...nd McHenry and will be open as follows: , &nbs...
(Date:11/25/2009)...RLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAme...ealthCareFraudActof2009,"S.2128,whichisdesignedtos...ventfraudinMedicare.ThebillwasintroducedbySen.Geor...eralprovisionstheAmericanAssociationforHomecareout...ociationproposedtoCongressinFebruary.Thoseprovisio...
(Date:11/25/2009)...disks placed under the skin kill tumor cells, stud...y News) -- A cancer vaccine delivered in a fingern...e, a new study reports. , The method uses polym...aded with tumor-specific antigens and implanted un...ack tumors. The Harvard University scientists who ...
Breaking Medicine News(10 mins):Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 2Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 3Health News:Centegra H1N1 Vaccination Clinics to Resume Tuesday, Dec. 1 4Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...actices resulted in Rajasthan's maternal mortality...n 1997 to 445, a decline of 34 percent, said Healt...han still lags far behind the national MMR average...as come down to 301 in 2002-03 from 398 in 1997-98...
...by hangover while teenagers have a greater resista...ologist Elena Varlinskaya and other researchers st...valent age to human teenagers and adults. Th...tion of Daily Mail. The dose given was equiv...
... injuries like low back pain and disc disorder now... could bring better results than conventional// su...edically known, has started gaining ground in west...jury is a better option than surgery. This new for...
...en have fewer long-term gastrointestinal side effe...RT) than with three-dimensional// conformal radiat..., despite the higher doses of radiation used in th...ciety for Therapeutic Radiology and Oncology in Ph...
...lled the silent killer, is steadily attacking mor...are of the disease// they are living with. In...d by the US . In fact one in six out of every Amer...t. Diabetes is a chronic metabolic disorder w...
...ghts body led by US-based AIDS researcher Kunal Sa...housands of people in West Bengal who are// feared...lt of faulty blood-test kits purchased by the stat...engal State AIDS Control and Prevention Society fl...
Other Medicine News:Health News:Older People Get Worse Hangovers 2Health News:Ozone Treatment - A Good Alternative For Spinal Injury 2Health News:IMRT Versus 3D CRT For Prostate Cancer, New Long-Term Data Assesses Side Effects 2Health News:Worldwide Diabetes Figures Alarmingly High 2Health News:Compensation Demanded For Bengal's Blood Scam Victims 2
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: